Pharmaceuticals are shown in North Andover, Mass. A revamped North American trade deal is nearing passage in Congress, giving both the White House and House Democrats cause to claim victory. There is relief, too, for farmers and businesses that wanted clearer rules governing the vast flow of goods among the United States, Canada and Mexico. But the pact left at least one surprising loser: The pharmaceutical industry, a near-invincible lobbying powerhouse in Washington. File photo by THE ASSOCIATED PRESS

Pharmaceuticals are shown in North Andover, Mass. A revamped North American trade deal is nearing passage in Congress, giving both the White House and House Democrats cause to claim victory. There is relief, too, for farmers and businesses that wanted clearer rules governing the vast flow of goods among the United States, Canada and Mexico. But the pact left at least one surprising loser: The pharmaceutical industry, a near-invincible lobbying powerhouse in Washington. File photo by THE ASSOCIATED PRESS

North America trade pact deals rare setback to Big Pharma

A revamped North American trade deal nearing passage in Congress gives both the White House and Democrats a chance to claim victory and offers farmers and businesses clearer rules governing the vast flow of goods among the United States, Canada and Mexico.

But the pact leaves at least one surprising loser: the pharmaceutical industry, a near-invincible lobbying powerhouse in Washington.

To satisfy House Democrats, the Trump administration removed a provision that would have given the makers of ultra-expensive biologic drugs 10 years of protection from less expensive knockoffs. Democrats opposed what they called a giveaway to the industry that could have locked in inflated prices by stifling competition. Top examples of the injected drugs made from living cells include medications to fight cancer and immune disorders such as rheumatoid arthritis.

“This is one of the first times we’ve actually seen pharma lose,” said Rep. Earl Blumenauer, an Oregon Democrat who leads a subcommittee on trade. “They have a remarkable track record because they are a huge political force. They spend lots of money on lobbying, on advertising, on campaign contributions. But we held firm, and we won on all counts.”

The removal of the provision also helped illustrate just how potent a political issue sky-high drug prices have become. It was a reminder, too, that President Donald Trump repeatedly pledged to work to lower drug prices.

Last week, drug manufacturers absorbed another — though likely only temporary — defeat when House Democrats passed legislation, along party lines, that would authorize Medicare to use its influence in the marketplace to negotiate lower prices from drug companies. The bill is thought to have no chance of passage, though, in the Republican-led Senate.

Yet the revamped U.S.-Mexico-Canada Agreement, Trump’s rewrite of the 25-year-old North American Free Trade Act, seems set to clear Congress without the biologics protection that the drug industry had sought. , the House The full House voted 385-41 on Thursday to approve it. The Senate isn’t likely to take it up until January.

“It’s not a mystery,” said Rep. Jan Schakowsky, an Illinois Democrat who helped negotiate with the administration. “If you poll the American people, the cost of pharmaceuticals is a really big deal. It’s at the top of the list.”

The trade agreement the administration reached last year with Mexico and Canada gave biologics 10 years of protection from cheaper near-copies known as biosimilars. Among the leading biologics are the anti-cancer drug Rituxan and Humira and Enbrel, which fight immune disorders.

The industry — and the Trump administration — had argued that manufacturers of biologics require years of protection to profit from their drugs before biosimilars should be allowed to cut into sales. Otherwise, they contend, brand-name drug companies and biotech startups that rely on money from venture capital firms would have little incentive to invest in developing new medicines.

“The announcement made today puts politics over patients,” the leading drug industry trade group, PhRMA, said in a statement last week. “Eliminating the biologics provision in the USMCA removes vital protections for innovators while doing nothing to help U.S. patients afford their medicines or access future treatments and cures.”

The industry also rejected the notion that the biologics provision would keep drug prices high and hurt consumers. Existing U.S. law, they noted, already gives makers of biologics 12 years’ protection, more than the proposed 10 years in the USMCA. But the provision the Democrats succeeded in removing would have forced Mexico to expand biologics’ monopoly from five years and Canada from eight, potentially hurting U.S. consumers who seek lower drug prices in those countries.

What’s more, Democrats argued, if Congress had expanded the biologics’ monopoly in the USMCA, it would have prevented lawmakers from ever scaling back that monopoly to, say, the seven years that the Obama administration had once proposed.

“We would have been locked in,” Schakowsky said.

For Big Pharma, the setback marked a sharp turnabout. Four years ago, the drug industry helped scuttle an Obama administration trade deal with 11 Pacific Rim countries, arguing that a provision establishing eight years of protection for biologics was not sufficient. Now the latest U.S. trade deal contains no biologics protections at all.

Back in 2006, the industry scored a major victory when it helped push legislation through Congress that added prescription drug coverage for Medicare recipients but barred the government from negotiating lower prices. That restriction opened a “Pandora’s box” that paved the way for unsustainable price hikes, said Steve Brozak, an analyst at WBB Securities.

Drug makers began raising prices of existing drugs several times a year, sometimes totalling more than 20% annually. They also started launching biologics with list prices topping six figures a year. In May, U.S. regulators approved a one-time gene therapy, Zolgensma, with an eye-popping price of $2.1 million per patient.

A backlash has been growing, especially after news reports and congressional hearings exposed stories of patients rationing medicine and even dying because they couldn’t afford insulin or other drugs.

Drugmakers have “been on defence more than we’ve ever seen,” said David Certner, legal counsel for AARP.

Last year, Certner noted, Congress dealt the industry two losses: First, by increasing the discounts that drug makers must give to seniors with high drug costs who have landed in a Medicare coverage gap. Then, months later, lawmakers rejected industry efforts to reverse that change.

And in January, the industry lost perhaps its biggest champion in Congress when Sen. Orrin Hatch, R-Utah, retired.

Trump has long promised to address drug prices. On Wednesday, the administration moved ahead with a plan to allow Americans to safely and legally gain access to lower-priced medicines from abroad. So far, most of Trump’s drug-price initiatives have gone nowhere. His trade team negotiated biologics protections into the USMCA.

Facing public anger, Democratic resistance and the fact that Canada and Mexico had no reason to support the protections for biologics, the administration yielded. When it reached a deal with House Democrats on the USMCA last week, the biologics provision was out.

“Clearly, getting rid of the biologic provision was a step backwards,” U.S. Trade Representative Robert Lighthizer said Tuesday in an interview with the Fox Business Network. “And that was a compromise. You know, there are consequences of the Democrats’ control of the House. And that was necessary. And I’m sorry about that.”

Jeffrey Francer, general counsel for the Association for Accessible Medicines, which represents generic and biosimilar drug companies, put it another way: “The president decided not to fall on his sword for Big Pharma.”

Just Posted

Shanna Lydiard is upset to have had mail delivery cut off last month to her West Park street because of water main reconstruction. Delivery is to resume by May 19 at the latest, according to the City of Red Deer. (Photo by LANA MICHELIN/Advocate staff).
Red Deer woman frustrated by mail delivery suspension due to construction

Shanna Lydiard said residents shouldn’t have to drive across the city for their mail

Innisfail-Sylvan Lake MLA Devin Dreeshen received his COVID-19 vaccine Tuesday at Jackson’s Pharmacy in Innisfail. (Devin Creeshen Twitter photo)
COVID-19: Most local MLAs have received their first vaccine shot

Alberta’s NDP is encouraging all MLAs to get vaccinated and publicly promote… Continue reading

Alberta continues to wrestle with high COVID-19 case numbers. (NIAID-RML via AP)
Red Deer up to 858 active cases of COVID-19

Province reports additional 1,799 cases of the virus

Bo's Bar and Grill owner Brennen Wowk said the hospitality industry is looking for more clarity from the province around what conditions must be met to allow for restaurants reopening.
(Advocate file photo)
Frustated restaurant owners want to know government’s reopening plan

Restaurant owners feel they are in lockdown limbo

The Bowden Institution medium security facility near Bowden has 15 active COVID-19 cases. (THE CANADIAN PRESS/Jeff McIntosh)
15 active COVID-19 cases at Bowden prison

Bowden Institution has had 36 positive cases this year with 21 recovered and no deaths

Red Deer Mayor Tara Veer and several members of city council helped kick off the spring Green Deer cleanup campaign on Wednesday. Veer said city workers do their best to keep the city looking good, but need volunteer help to get rid of litter that has blown into bushes onto road sides over the winter. (Photo by LANA MICHELIN/Advocate staff)
Red Deer city councillors launch spring Green Deer campaign

Volunteers are needed to keep the city looking good

FILE - In this Feb. 29, 2020, file photo, National Rifle Association Executive Vice President and CEO Wayne LaPierre speaks at Conservative Political Action Conference, CPAC 2020, in Oxon Hill, Md. Federal Judge Harlin Hale announced his decision Tuesday, May 11, 2021, to dismiss the National Rifle Association's bankruptcy case over whether the powerful gun-rights group should be allowed to incorporate in Texas instead of New York, after 11 days of testimony and arguments. Lawyers for New York and the NRA's former advertising agency grilled the group's embattled top executive, LaPierre, who acknowledged putting the NRA into Chapter 11 bankruptcy without the knowledge or assent of most of its board and other top officers. (AP Photo/Jose Luis Magana, File)
Judge dismisses NRA bankruptcy case in blow to gun group

Judge dismisses NRA bankruptcy case in blow to gun group

Hassan Diab holds a news conference on Parliament Hill, in Ottawa Friday, February 7 , 2020.  THE CANADIAN PRESS/Fred Chartrand
Canada must not extradite Diab regardless of coming French court decision: lawyer

Canada must not extradite Diab regardless of coming French court decision: lawyer

Vancouver mayor-elect Kennedy Stewart addresses supporters in Vancouver on Sunday, Oct. 21, 2018. Vancouver's mayor says he understands that some drug users aren't happy with the city's proposed model for decriminalization but time is of the essence and the details can be worked out later. THE CANADIAN PRESS/Darryl Dyck
Vancouver mayor says there’s no time for drug decriminalization redo

Vancouver mayor says there’s no time for drug decriminalization redo

The RCMP logo is seen outside Royal Canadian Mounted Police "E" Division Headquarters, in Surrey, B.C., on Friday, April 13, 2018. THE CANADIAN PRESS/Darryl Dyck
Saskatchewan Mountie charged with first-degree murder after man found dead in woods

Saskatchewan Mountie charged with first-degree murder after man found dead in woods

Garneau quarantine travel to Iceland raises government confusion over rules

Garneau quarantine travel to Iceland raises government confusion over rules

Bloc Quebecois Leader Yves-Francois Blanchet rises during question period in the House of Commons on Parliament Hill in Ottawa on Wednesday, May 12, 2021. After repeatedly voting non-confidence in the minority Liberal government, the Bloc Quebecois is now calling on the government to do everything possible to avoid an election during the COVID-19 pandemic. THE CANADIAN PRESS/Sean Kilpatrick
BQ calls on Liberals to avoid pandemic election, despite voting non-confidence

BQ calls on Liberals to avoid pandemic election, despite voting non-confidence

U.K. study says expect more reactions from mixing Pfizer and AstraZeneca vaccines

U.K. study says expect more reactions from mixing Pfizer and AstraZeneca vaccines

In this Monday, March 15, 2021 file photo a vial of AstraZeneca vaccine is pictured in a pharmacy in Boulogne Billancourt, outside Paris. Questions remained Wednesday about the future of the Oxford-AstraZeneca vaccine in Canada, as Manitoba limited use of the shot and Ontario announced it planned to save an incoming shipment to use as second doses.  THE CANADIAN PRESS/AP/Christophe Ena, File
Questions remain about the future of the Oxford-AstraZeneca shot in Canada

Questions remain about the future of the Oxford-AstraZeneca shot in Canada

Most Read